PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Rifaximin 550mg tablets - Hepatic encephalopathy

PAD Profile : Rifaximin 550mg tablets - Hepatic encephalopathy

Keywords :
NICE, AMBER, Shared Care, antibiotic, antibacterial
Brand Names Include :
Targaxan

Traffic Light Status

Status 1 of 1.

Status :
Blue
Important
Formulations :
  • Tablets
Important Information :
Restricted use on recommendation of Gastroenterology consultants for treatment of hepatic encephalopathy.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
R
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

Type
Document
Review Date
Guidelines (Local)
Rifaximin for Overt Hepatic Encephalopathy -Treatment Pathway - Aug 2021.pdf
01 August 2024
NICE Technology Appraisal
NICE TA337 - Rifaximin for prevention of Hepatic Encephalopathy

Committee Recommendations

Date
Committee Name
Narrative
04 August 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed that rifaximin for the reduction in  recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age, has a BLUE (with flow chart/pathway) traffic light status. See below for agreed documentation

Associated BNF Codes

05. Infections
05.01.07. Some other antibacterials
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More